Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Industry: Healthcare

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b trial to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.

Current Quote*
Last: $22.720
Change: 0.360
Book: $2.769
Volume: 210,674

As Of: 11/16 15:57 ET
*Quotes delayed by 20min.

Graphs for DCPH


3 Month Graph


6 Month Graph


1 Year Graph